The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
This study is currently recruiting participants.
(see Contacts and Locations)
Verified November 2014 by Showa Inan General Hospital
Sponsor:
Showa Inan General Hospital
Information provided by (Responsible Party):
Akira Horiuchi, Showa Inan General Hospital
ClinicalTrials.gov Identifier:
NCT00596401
First received: January 8, 2008
Last updated: November 12, 2014
Last verified: November 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.
| Condition |
|---|
|
Helicobacter Pylori Eradication Gastric Cancer Medical Care Cost |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town |
Resource links provided by NLM:
Further study details as provided by Showa Inan General Hospital:
Primary Outcome Measures:
- the annual incidence of gastric cancer in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The annual medical care cost in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
serum
| Estimated Enrollment: | 3000 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | August 2017 |
| Estimated Primary Completion Date: | August 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
HP eradication group
|
|
2
No eradication group
|
|
3
No Hp group
|
Eligibility| Ages Eligible for Study: | 19 Years to 69 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
People who live in Iijima town
Criteria
Inclusion Criteria:
- People who live in Iijima town at their age of 19 to 69 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596401
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596401
Contacts
| Contact: Akira Horiuchi, M.D. | 81265822121 ext 3012 | horiuchi.akira@sihp.jp |
Locations
| Japan | |
| Showa Inan General hospital | Recruiting |
| Komagane, Nagano, Japan, 399-4191 | |
| Contact: Akira Horiuchi, M.D. 81265822121 ext 3012 horiuchi.akira@sihp.jp | |
| Principal Investigator: Akira Horiuchi, M.D. | |
Sponsors and Collaborators
Showa Inan General Hospital
Investigators
| Study Director: | Akira Horiuchi, M.D. | Showa Inan General Hospital |
More Information
No publications provided
| Responsible Party: | Akira Horiuchi, Digestive Disease Center, Showa Inan General Hospital |
| ClinicalTrials.gov Identifier: | NCT00596401 History of Changes |
| Other Study ID Numbers: | sihp20076 |
| Study First Received: | January 8, 2008 |
| Last Updated: | November 12, 2014 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Additional relevant MeSH terms:
|
Stomach Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases |
Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases |
ClinicalTrials.gov processed this record on March 01, 2015